Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Chimeric antigen receptor (CAR) immunotherapy is one of the most promising modern approaches for the treatment of cancer. To date only two CAR T-cell products, Kymriah<sup>®</sup> and Yescarta<sup>®</sup>, have been approved by the Food and Drug Administrati...
Main Authors: | Aleksei Titov, Aygul Valiullina, Ekaterina Zmievskaya, Ekaterina Zaikova, Alexey Petukhov, Regina Miftakhova, Emil Bulatov, Albert Rizvanov |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/1/125 |
Similar Items
-
Adoptive Immunotherapy beyond CAR T-Cells
by: Aleksei Titov, et al.
Published: (2021-02-01) -
Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections
by: Ekaterina Zmievskaya, et al.
Published: (2021-01-01) -
A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
by: Faroogh Marofi, et al.
Published: (2021-06-01) -
Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap
by: Frederick L. Locke, et al.
Published: (2017-07-01) -
CAR T cells in solid tumors: challenges and opportunities
by: Faroogh Marofi, et al.
Published: (2021-01-01)